Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label study of AS-0141 in advanced or refractory malignancies
jRCT2031210072Phase 1Active, not recruiting
- Sponsor
- Carna Biosciences, Inc.
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of monzosertib in Nonhematologic neoplasms, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 1 more, sponsored by Carna Biosciences, Inc. Primary endpoint: Dose limiting toxicity. Started Jun 2021; status: active, not recruiting.
02
Drugs
monzosertib
03
Conditions
Nonhematologic neoplasmsacute myeloid leukemia (AML)myelodysplastic syndrome (MDS)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2031210072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210072.